Skip to content

Warby Parker

US · WRBY #2446 by market cap Listed 2021
23.12 -1.01 -4.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 8.46 Expensive vs history 76th percentile
5-year average 7.26 · #45 of 51 in Medical Instruments & Supplies
P/E ratio 457.33 Expensive vs history 90th percentile
5-year average 203.32 · forward 68.81 · #26 of 27 in Medical Instruments & Supplies
P/S ratio 3.65 Expensive vs history 74th percentile
5-year average 3.43 · forward 3.02 · #35 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Warby Parker (WRBY) 2.87B 385.33 7.12 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value27.69 Economic moatNone UncertaintyHigh

Trading 19.8% below Morningstar's fair value estimate.

Fair value

Warby Parker Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The firm's lack of profitability undermines our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of 1.1% ranks in the bottom 40% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which contributes to our balanced fair value estimate.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 12.8%, for example, lies in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Warby Parker discussion 0 comments

Add a comment